RNA toxicity is implicated in a number of disorders; especially those associated with expanded repeat sequences, such as myotonic dystrophy (DM1). Previously, we have shown increased NKX2-5 expression in RNA toxicity associated with DM1. Here, we investigate the relationship between NKX2-5 expression and muscle pathology due to RNA toxicity. In skeletal muscle from mice with RNA toxicity and individuals with DM1, expression of Nkx2-5 or NKX2-5 and its downstream targets are significantly correlated with severity of histopathology. Using C2C12 myoblasts, we show that over-expression of NKX2-5 or mutant DMPK 3 ′ UTR results in myogenic differentiation defects, which can be rescued by knockdown of Nkx2-5, despite continued toxic RNA expression. Furthermore, in a mouse model of NKX2-5 over-expression, we find defects in muscle regeneration after induced damage, similar to those seen in mice with RNA toxicity. Using mouse models of Nkx2-5 over-expression and depletion, we find that NKX2-5 levels modify disease phenotypes in mice with RNA toxicity.
INTRODUCTION
Myotonic dystrophy (DM1) is an autosomal dominant disorder caused by an expanded (CTG) n tract in the 3 ′ untranslated region (3 ′ UTR) of the dystrophia myotonica protein kinase (DMPK) gene resulting in nuclear entrapment of the 'toxic' mutant RNA and interacting RNA-binding proteins (1 -3) . DM1 is a multi-systemic disorder characterized by progressive muscle wasting, and the first example of a disease caused by RNA toxicity. Mutant DMPK mRNAs form nuclear aggregates and are thought to mediate adverse effects by affecting interactions with or altered activity of RNA splicing factors such as Muscleblind-like 1(MBNL1) and CUG-binding protein 1 (CELF1), resulting in aberrant splicing of various target mRNAs in affected tissues.
The major debilitating factor in DM1 is muscle wasting. Previously, we found that expression of the mutant DMPK 3 ′ UTR mRNA in C2C12 mouse myoblasts results in defective myogenic differentiation (4 -7) . Several other groups have also reported differentiation defects (8 -11) or in one case, normal differentiation but abnormal apoptosis (12) using primary myoblasts from DM1 patients. Using two separate inducible-reversible transgenic mouse lines of RNA toxicity, we demonstrated that overexpression of DMPK-3 ′ UTR mRNAs reproduced many disease features including characteristic histologic abnormalities, severe muscle pathology, CELF1 up-regulation, RNA splicing defects, myotonia, cardiac conduction defects and showed that they are potentially reversible (13) . Additionally, we have shown that the phenotype in these mice can be modulated by altering their genotype or doxycline dosage, or CELF1 levels (14) . Also we have shown that the transgene transcript in these mice interacts with MBNL1 (15) and that over-expression of MBNL1 can modulate phenotypes such as altered splicing and myotonia in these mice, similar to what has been demonstrated in other mouse models of RNA toxicity (16) . Unexpectedly, we also found induction of NKX2-5 in skeletal muscles, a result that was confirmed in skeletal muscles from DM1 patients (17) . During mouse development, NKX2-5, a transcription factor, is detected in cardiac progenitors and pharyngeal endoderm as early as 7.5-day post-coitum (18, 19) and is also detected in a subset of cranial skeletal muscles, spleen, stomach, liver, tongue and anterior larynx (20) . However, in adult mice and humans, its expression is primarily restricted to cardiac tissues; it is not expressed in skeletal muscles. The homozygous deletion of Nkx2-5 in mice is lethal at early stages of cardiac development, and therefore, it has been difficult to study the function of NKX2-5 in the development of other organs as † These authors contributed equally to this work.
well as in the differentiation and maturation of cardiac myocytes (21) . The effects of NKX2-5 in skeletal muscle have not been studied thus far. Here, we sought to understand the role of increased NKX2-5 levels in skeletal muscle pathology due to RNA toxicity using myoblast cell culture models, transgenic mouse models of RNA toxicity and transgenic and knockout mouse models of NKX2.5.
RESULTS

NKX2-5 mRNA levels correlate with muscle histopathology in mice and humans
We analyzed the skeletal muscles from our doxycycline inducible mouse models of RNA toxicity where NKX2-5 expression is induced in multiple transgenic lines (5 -313 and 5 -336) (17) . In these mice, over-expression of a mRNA containing a normal DMPK 3
′ UTR with only (CUG) 5 mimics the toxicity of the mutant DMPK transcript. We can induce differing levels of DM1 pathology in these mice by altering their genotype (hemizygous or homozygous for the transgene locus) and the dosage of doxycycline. DM1 histopathology is typically characterized by progressive myopathic changes ranging from central nucleation, fiber atrophy and damage, leading eventually to fibrosis and fatty infiltration. Figure 1A and Supplementary Material, Figure S1 depict typical findings with hematoxylin and eosin (H&E)-stained muscle sections in this model. A quantitative histopathology scale was applied by an observer blinded to the genotype and disease status of the mice (n ¼ 34) to determine the extent of the histopathology. Next, we analyzed the expression of Nkx2-5 mRNA by reverse-transcription polymerase chain reaction (RT-PCR) in the same muscles and determined if there was any correlation between Nkx2-5 expression and histopathology. As shown in Figure 1B , Nkx2-5 mRNA expression is higher in the muscles with moderate to severe pathology (n ¼ 17, grades 2 -3) as compared with muscles with mild pathology (n ¼ 12, grade 1), and it is undetectable in normal muscles (n ¼ 5, grade 0). By quantitative RT-PCR (qRT-PCR), we observed a significant correlation between Nkx2-5 transcript levels and severity of muscle histopathology (P , 0.05, ANOVA) (Fig. 1C) . We also assessed the expression of Nppa [atrial natriuretic peptide (ANP)] and Nppb [brain natriuretic peptide (BNP)] by RT-PCR (Fig. 1B) and Gata4 expression by qRT-PCR (Supplementary Material, Fig. S2 ) and found increased expression of all three transcripts in muscles with severe histopathology as compared with mild histopathology. Additionally, we observed a significantly higher level of Gata4 mRNA in severely affected muscles as compared with mildly affected muscles (P , 0.041), or unaffected muscles (P , 0.002) (Supplementary Material, Fig. S2 ). In normal muscles, the expression of these mRNAs was either not detectable or extremely low.
To determine the specificity of Nkx2-5 mRNA expression, we checked by RT-PCR, the expression of Nkx2-5 and one of its downstream targets, Nppb, in skeletal muscles of several other mouse models. The HSA-LR mouse (a widely used mouse model for DM1) expresses a skeletal muscle actin transgene with a (CTG) 250 tract in its 3 ′ UTR (22) ; the Clcn1 2/2 mouse is a model of myotonia caused by the absence of chloride channel (23) ; the MDX mouse is a model of Duchenne muscular dystrophy (DMD) (24) and the green fluorescent protein (GFP) mouse expresses GFP widely (25) and was used to control for effects of GFP. Notably, despite the presence of obvious myopathy and histopathology in the HSA-LR, Clcn1 2/2 and the MDX mice (Supplementary Material, Fig. S1 ), we found that Nkx2-5 and Nppb mRNAs are present only in the mice with DMPK 3 ′ UTR mRNA toxicity (Fig. 1D ). This suggests that the results are not due to a non-specific response to myopathy. Similarly, it is not a response to myotonia, because both the HSA-LR and the Clcn 2/2 mice have extensive myotonia. Nor is it a response to GFP expression. Additionally we examined skeletal muscle from Mbnl1 2/2 and a Mbnl1 2/2 /Mbnl2 +/2 mice (26) and found no expression of Nkx2-5 (data not shown).
To assess possible relevance to DM1, we analyzed skeletal muscle samples from DM1 patients by western blotting, qRT-PCR and immunofluorescence. We observed variable NKX2-5 expression and assessed if expression of NKX2-5 correlated with the severity of muscle pathology, as in our mouse models. Figure 1E and Supplementary Material, Figure S3 depict representative H&E pictures of variably affected muscles from DM1 patients, and a sample from a severely affected DMD patient. Compared with mildly affected muscles from DM1 patients, western blotting showed that NKX2-5 protein levels were approximately 5-fold higher in muscles with severe histopathology (Fig. 1F, upper panel) . In contrast, muscles from patients with DMD or other muscular dystrophies, and normal muscles did not express NKX2-5. Samples from two DM2 patients were also analyzed, but the results showed no consistent evidence of increased NKX2-5 expression. We found similar results with RT-PCR (Fig. 1F, lower panel) . Although sample numbers were limited, we found a clear and statistically significant correlation (P , 0.05, ANOVA) between histopathology grade and qRT-PCR for NKX2-5 expression in DM1 samples (Fig. 1G) . Indirect immunofluorescence for NKX2-5 showed expression in skeletal muscles from DM1 patients (Fig. 1H) . These results support the validity of the findings from our mouse model.
We also analyzed the expression of NKX2-5 target genes (NPPA and NPPB) (ANP and BNP) and other cardiac transcription factors (GATA4, TBX5, and TBX20) (Supplementary Material, Fig. S4 ). These genes were not expressed at appreciable levels in unaffected human skeletal muscles. We found increased levels of NPPA, NPPB, GATA4, TBX20 and TBX5 mRNA only in severely affected DM1 muscles. The expression of TBX5 was also seen in DMD muscles. These results demonstrate that the expression of NKX2-5 downstream targets also seem to correlate with muscle histopathology in DM1.
Nkx2-5 contributes to myogenic differentiation defects in a C2C12 cell culture model of RNA toxicity Previously, we found that expression of the mutant DMPK 3 ′ UTR mRNA in C2C12 mouse myoblasts results in defective myogenic differentiation (4 -7). Using qRT-PCR, we found that Nkx2-5 mRNA levels were clearly induced, more than 20-fold in cells expressing the DMPK 3 ′ UTR (CTG) 200 mRNA (termed GFP-200 or DM200), and increased about 3.8-fold in the cells expressing the DMPK 3 ′ UTR (CTG) 5 mRNA (termed GFP-5 or DM5), as compared with wild-type C2C12 cells ( Fig. 2A) with the GFP-5 cells (Fig. 2B ), demonstrating that both repeat length and overall quantity of DMPK 3 ′ UTR mRNA are capable of increasing Nkx2-5 expression.
To confirm that the increased Nkx2-5 expression in the GFP-200 cells was due to this mRNA, we used short hairpin RNAs (shRNAs) against GFP to knockdown toxic RNA expression. Using qRT-PCR for GFP mRNA, we consistently found (n ¼ 6 independent transfections) that the shRNA reduced GFP expression by about 70% as compared with control experiments using a non-specific shRNA (P , 0.014). Concomitantly, we found an approximately 30% reduction in Nkx2-5 mRNA as compared with controls (P , 0.004), demonstrating that induction of Nkx2-5 expression is directly related to the expression of mutant DMPK 3 ′ UTR transcripts (Fig. 2C) . We have previously shown that myogenic differentiation defects in the C2C12 RNA toxicity model are associated with reduced levels of MyoD, p21 and myogenin (5,6). To determine whether over-expression of NKX2-5 also plays a role in the myogenic defects, we transiently transfected the GFP-200 cells with plasmids expressing shRNA sequences against Nkx2-5. This enabled reduction of Nkx2-5 expression in cells that continued to express the toxic RNA. Subsequently, the cells were differentiated for 3 days and then analyzed for myosin heavy chain (MHC) expression by immunofluorescence, western blotting and qRT-PCR. As shown in Figure 2D and E, immunostaining for MHC expression revealed a clear increase in its expression in cells treated with Nkx2-5 shRNA as compared with control shRNA (P , 0.001 for shNk1 and shNk3). This was also confirmed by qRT-PCR (P ¼ 0.005 for shNk1 and P ¼ 0.06 for shNk3) and western blot analysis for MHC ( Fig. 1F and G). We confirmed that the different Nkx2-5 shRNAs caused a 50-90% reduction in Nkx2-5 mRNA (P ¼ 0.25 for shNk1 and P ¼ 0.0005 for shNk3) while leaving the toxic RNA expression (GFP) unaffected (Fig. 2H ). These results show that key aspects of the myogenic defects associated with the toxic RNA are mediated through induced Nkx2-5 over-expression.
To determine which steps in myogenic differentiation are affected by Nkx2-5, we also analyzed the expression of Myod1, Myog and Cdkn1a (p21) mRNAs by qRT-PCR in cycling and differentiating cells (6 and 12 h after induction of differentiation) treated with the Nkx2-5 shRNAs (Fig. 2H ). The expression of Myod1 was not affected by reduced levels of Nkx2-5 expression. However, Myog mRNA increased up to 20-fold in cycling cells, and 2-to 4-fold in differentiating cells. We also found Cdkn1a mRNA is increased in cycling cells up to 6-fold and 2-fold in differentiating cells. We also looked at miR-1 in cycling DM200 cells. miR-1 is another factor important for proper myogenic differentiation and has been previously shown to be regulated by NKX2-5 (27) . We found an 80% reduction of miR-1 in the DM200 cells (P , 0.01) (Fig. 2I) . In DM200 cells treated with the Nkx2-5 shRNAs, we found that as Nkx2-5 levels fell there was a corresponding increase in miR-1 levels (P ¼ 0.05 for miR-1 levels using shNk3) (Fig. 2J ). These results demonstrate that in cells expressing the toxic RNA, increased Nkx2-5 contributes to the down-regulation of Myog, Cdkn1a and miR-1, factors essential to the proper regulation of myogenic differentiation.
Over-expression of NKX2-5 inhibits C2C12 myogenic differentiation
To directly study the effects of NKX2-5 on myogenic differentiation, we made C2C12 cell lines over-expressing Nkx2-5. Upon differentiation, these cells failed to fuse and form myotubes (Fig. 3A) . In these cells, Nkx2-5 mRNA was increased 15-fold in growth conditions (d0), and 8-fold in differentiating conditions (48 h, d2) as compared with wild-type C2C12 cells (Fig. 3B ). We also analyzed the expression of Myod1, Myog and Cdkn1a in growth and differentiation promoting conditions by qRT-PCR and western blotting ( Fig. 3B and C). We found that mRNA expression of Myog, but not Myod1, is reduced in conditions of growth (by 90%) as well as differentiation (by 75%) in cells over-expressing NKX2-5. These results were supported by western blotting. Additionally, we found that p21 protein levels were dramatically reduced under differentiation conditions, despite only a modest (20-30%) decrease in the Cdkn1a mRNA. Analysis by qRT-PCR also showed a .50% reduction in Myh2 mRNA expression in cells differentiated for 2 and 4 days (Fig. 3B) . Consistent with this, we found reduced levels of MHC expression by western blotting (Fig. 3C ).
When miR-1 was measured by qRT-PCR in these cell lines, we found a statistically significant decrease in miR-1 levels (P ¼ 0.04) (Fig. 3D ). It has been demonstrated that overexpression of NKX2-5 in HL-1 cells (a mouse cardiomyocyte cell line) led to a reduction in miR-1, while Nkx2-5 2/2 mouse embryos had an increase in miR-1 levels relative to controls (27) . Furthermore, this group identified a 2.6-kb miR-1 enhancer region containing four NKX2-5 binding sites, that when mutated, rendered transcription from a luciferase reporter gene insensitive to NKX2-5 levels, demonstrating that NKX2-5 acted as a transcriptional repressor of miR-1 expression. To confirm these findings in our C2C12 cell lines, we generated a luciferase construct containing the four NKX2-5 sites. When transfected into our NKX2-5 over-expression cell line, we also saw a decrease in luciferase levels relative to the control C2C12 lines (P ¼ 0.015) (Fig. 3E ). These results demonstrate that NKX2-5 over-expression in differentiating myoblasts has striking, deleterious effects on myogenin, p21 and miR-1, all key players in the myogenic differentiation process. They are also consistent with the data shown in Figure 2 , in which the knockdown of Nkx2-5 in C2C12 cells expressing the toxic RNA achieved a substantial rescue of myogenin, p21 and miR-1 levels and myogenic differentiation. 256
NKX2-5 modifies phenotypic severity in a mouse model of RNA toxicity
To examine the role of NKX2-5 over-expression in skeletal muscle, we generated a NKX2-5 over-expressing transgenic mouse line (TgNkx2-5) under the control of the same DMPK promoter used to make the RNA toxicity mice. This promoter was chosen so that NKX2-5 tissue expression would mirror that of the toxic RNA expression. The TgNkx2-5 mice were born smaller than their wild-type littermates and had an increased mortality (Fig. 4A-C) . While not limited to skeletal muscle, NKX2-5 expression was clearly detected in muscle by western blot and immunofluorescence staining ( Fig. 4D  and E) . Levels of the protein and RNA were within the ranges observed in the severely affected DM1 samples. Using functional assays, we determined that these mice had decreased grip strength as early as 1 month of age and were less capable of running as compared with their control littermates (Supplementary Material, Fig. S5 ). Interestingly, their skeletal muscle showed no striking histopathology, and the fiber size distribution was similar between the TgNkx2-5 mice and the wild-type control littermates (Fig. 4F) . However, Myog (P ¼ 0.05) and miR-1 (P ¼ 0.13) levels were decreased similar to the results seen in the NKX2-5 over-expressing C2C12 cell lines (Fig. 4G ).
To determine if increasing levels on NKX2-5 can modify DM1 phenotypes, we crossed the TgNkx2-5 mice to homozygous DM5-313 +/+ mice. The resulting offspring (TgNkx2-5/ 5-313 +/2 and 5 -313 +/2 ) were either induced with the administration of doxycycline or left uninduced as controls. After 4 weeks of induction, the mice over-expressing NKX2-5 had significant decreases in retained grip strength (P ¼ 0.011) and run distance (P ¼ 0.001) as compared with the induced 5 -313
littermates (Fig. 5A) . In addition, skeletal muscle histopathology was worse, with an increased number of small fibers compared with the control littermates ( Fig. 5B and Supplementary Material, Table S1 ). These results showed that NKX2-5 is a modifier, as over-expression of NKX2-5 worsened the effects of RNA toxicity in our mice.
However, as we only had one line of mice over-expressing NKX2-5, we sought alternative ways to determine if NKX2-5 modifies RNA toxicity. On the basis of the above results, we inferred that reducing NKX2-5 levels may lessen the effects of RNA toxicity. To test this hypothesis, we crossed the 5 -313 mice with mice that had reduced NKX2-5 levels (Nkx2-5
LacZ/+ ) (17, 28) . The Nkx2-5
LacZ/+ mouse contains a LacZ cassette in the first exon of the Nkx2-5 gene. Homozygous mice from this line are embryonic lethal, but the heterozygotes are healthy and viable with no evident muscle pathology. We confirmed Fig. S6 ) (17) . In the Nkx2-5
LacZ/+ / 5-313 +/2 mice induced for RNA toxicity, we saw a trend towards better grip strength as early as 2 and 4 weeks after induction and significant improvement in the muscle grip strength by 8 weeks of induction (P ¼ 0.015) as compared with the 5 -313 +/2 induced littermates (Fig. 5C ). Additionally we observed an improvement in muscle histopathology as measured by fiber diameter (Fig. 5D and Supplementary Material, Table S2 ). Notably, the reduction in Nkx2-5 did not alter Mbnl1 mRNA levels as assessed by qRT-PCR, nor change the RNA splicing changes defects present in the 5 -313 +/2 mice (Supplementary Material, Fig. S7 ). We also used another Nkx2-5 deficient transgenic mouse line, Nkx2-5
Cre/+ , in which an IRES/Cre cassette was inserted into the 3 ′ UTR of the Nkx2-5 gene (29) . This is thought to have generated a hypomorphic allele where NKX2-5 levels are only slightly reduced. Using these mice, we saw a trend towards increased grip strength as in the experiments with the Nkx2-5
LacZ/+ mice and reduced fiber size variability (Supplementary Material, Fig. S8 ). Taken together, these data provide strong evidence that NKX2-5 acts as a modifier of skeletal muscle pathology due to RNA toxicity.
Mice over-expressing the toxic RNA or NKX2-5 have defective muscle regeneration
The previous results clearly show that NKX2-5 is a modifier of the RNA toxicity with increased NKX2-5 leading to a worsened skeletal muscle histopathology and a worsened DM1 phenotype in our mouse model, and having a strong association with increased muscle pathology in individuals with DM1. To understand how NKX2-5 levels are modifying the pathology, we considered the observed phenotypes in our animal and cell culture models. There are a number of reports showing that incorrect regulation of the myogenic targets that we have demonstrated to be affected by NKX2-5 (i.e. miR-1, p21 and myogenin), lead to defects in myogenic differentiation (5, (30) (31) (32) . We hypothesized that the defects observed in the cell culture models could translate into skeletal muscle regeneration defects in mice.
To examine the effects of RNA toxicity on regeneration, we utilized a widely used injury-induced muscle regeneration model (33) (34) (35) . The injection of cardiotoxin (CTX) into muscle induces inflammation and myofiber degeneration that is followed by muscle regeneration. We used DM5-313 mice, which upon induction of RNA toxicity develop DM1 histopathology slowly. DM5-313 +/2 mice were either uninduced or induced for 14 days. At this point, the gastrocnemius muscles in each mouse were injected with either CTX or phosphate buffered saline (PBS) (in the contralateral leg) (Fig. 6A ). Tissues were collected at various days post-injection for further analyses. A more severe histopathology and significant differences in fiber size distributions were observed when comparing the induced and uninduced groups that received the CTX injection (P , 0.03) (Fig. 6B, C and Supplementary Material, Table S3 ). The induced group had both a smaller median fiber size in the damaged sections and an increase in the number of small fibers (fiber diameter ≤15 -20 mm). Additionally, the CTX damaged, DM5-Dox+ mice had a greater number of central nuclei still present in the damaged section. Notably, in the PBS-injected muscle of the uninduced and induced mice, the fiber size distribution and morphology were similar at 14-day post-injection (Supplementary Material, Table S3 ), showing that 4 weeks of RNA toxicity did not significantly alter the histopathology of the muscles. All of these observations are consistent with a delayed regenerative process and demonstrate that regeneration defects are present in the skeletal muscle of the mice with RNA toxicity even at a time point when there is no significant histopathology.
We went on to determine if the CTX injury model resulted in similar regeneration defects in the TgNkx2-5 mouse model. We found that as early as 5-day post injury and as late as 28 days, there was an increase in small fibers in the TgNkx2-5 +/2 mice as compared with the wild-type controls ( Fig. 6D and E) . Thus, over-expression of NKX2-5 results in regeneration defects similar to those caused by RNA toxicity.
Skeletal muscle regeneration relies upon muscle precursor cells known as satellite cells, which are normally quiescent but proliferate rapidly in response to damage and subsequently differentiate into myoblasts that fuse and regenerate muscle fibers. The transcription factor PAX7 plays a key role in satellite cells and is used commonly as a marker of satellite cells. Using PAX7 immunofluorescence as a marker of satellite cells (and satellite cells recently committed to the myoblast lineage), we examined PAX7 expression in the skeletal muscles of our DM5-313 RNA toxicity model. In non-damaged muscle, there were approximately three PAX7+ve nuclei per 100 muscle fibers in both the DM5-313-Dox-ve and DM5-313-Dox+ve mice. The number of PAX7+ve nuclei rose to 27 per 100 fibers in skeletal muscle of uninduced DM5-313 mice 5 days after CTX damage of the muscle, at a time when satellite cell and recently committed myoblast number is at its peak (34), indicating a robust proliferative response. In contrast, under the same conditions of CTX damage in the DM5-313 Dox+mice, the number of PAX7+ve nuclei was only 11 per 100 fibers, representing a 59% reduction (P , 0.001) (Fig. 7A) . These data clearly indicated that RNA toxicity led to a defect in satellite cell response to damage.
To evaluate if the defective regenerative response in the TgNkx2-5 mice could be due to a similar effect on satellite cells, we evaluated PAX7 expression in these mice. In nondamaged muscle, the number of PAX7+ve nuclei was roughly two per 100 muscle fibers in both the wild-type and TgNkx2-5 mice. Five days after CTX damage of the muscle, this rose to 31 per 100 fibers in wild-type mice. However, it was only 18 per 100 fibers in the damaged tissues from TgNkx2-5 +/2 mice, representing a 41% reduction (P ¼ 0.014) in the number of Pax7+ve nuclei (Fig. 7B) . Thus, both RNA toxicity and NKX2-5 over-expression were both associated with a similar defect in satellite cell behavior.
DISCUSSION
Previously, we reported that RNA toxicity induced NXK2-5 expression in cardiac and skeletal muscles in our RNA toxicity mouse models and in DM1 patient tissues (17) . The finding of NKX2-5 expression in skeletal muscle was unexpected. In this study, we find that in both mouse models of RNA toxicity and skeletal muscles from DM1 patients, the expression of NKX2-5 is correlated with severity of muscle histopathology (Fig. 1) . Although there is some evidence that it is expressed in a limited set of skeletal muscles during embryonic development, NKX2-5 is a cardiac transcription factor that is absent in mature skeletal muscle. In DM1, RNA toxicity leads to a more embryonic pattern of gene expression and RNA splicing (36) (37) (38) . The expression of NKX2-5 could be a further manifestation of this effect, but its significance is unknown. In this study, we set out to determine whether increased NKX2-5 levels have a role 
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Human Molecular Genetics, 2015, Vol. 24, No. 1 in skeletal muscle pathology due to RNA toxicity associated with DM1 phenotypes. DM1 muscle pathology is characterized by a progressive wasting of muscle that eventually leads to fibrosis and fatty infiltration. Unlike other muscular dystrophies such as DMD, where there is initially an active regeneration in skeletal muscle in response to the incurred damage, typical reports of DM1 muscle pathology often remark about the surprising lack of regeneration (8 -11) . The molecular basis of regeneration defects in DM1 skeletal muscle is still largely unexplored. In vivo, myoblasts (activated and committed satellite cells) differentiate and fuse to form new muscle fibers during muscle formation and regeneration. Recently, satellite cell dysfunction in damaged muscle fibers has been proposed for the progressive muscle wasting in DM1 (11) . The authors found an increase in the number of satellite cells without an increase in regenerating fibers. Others have reported differentiation defects using primary myoblasts from DM1 patients (8 -11) . Moreover, recent studies have shown impairment of muscle regeneration in muscleblind-like 3 (Mbnl3) knockout mice (33) . This is consistent with the data from our C2C12 model of RNA toxicity, where we have extensively demonstrated adverse effects of RNA toxicity on myogenesis (7). We have now also found increased Nkx2-5 expression in this model of RNA toxicity (Fig. 2) . Notably, when Nkx2-5 expression was knocked-down in these cells without affecting toxic RNA production, the resulting rescue of the expression of key markers of myogenic progression [i.e. increased Myh2, Myog, Cdkn1a (p21) and miR-1 expression] showed that Nkx2-5 over-expression contributes significantly to the myogenic defects caused by the mutant DMPK 3 ′ UTR mRNA. Here, we also found that over-expression of NKX2-5 in C2C12 myoblasts also inhibits differentiation and myoblast fusion (Fig. 3) . Increased NKX2-5 inhibited the expression of myogenin and p21, key players in myogenic differentiation along with miR-1, a microRNA (miRNA) shown to be vital for myogenic differentiation (30, 39) . Of note, the effect on p21 may be mediated through additional miRNA regulation, as NKX2-5 has been shown also to affect the expression of the miR-17-92 cluster, which has been shown to affect p21 (40, 41) .
Although cell culture myoblast models, such as our C2C12 model of RNA toxicity, have a defined utility in studying aspects of RNA toxicity, there are limitations to extrapolating the results to an in vivo situation. Therefore, we used mouse models to study the effects of NKX2-5 and RNA toxicity. The eGFP transgene expressing the toxic RNA was driven by a human DMPK promoter in an attempt to mimic the expression of DMPK (13) . To reproduce the expression pattern of the toxic RNA, we used the same promoter construct to generate NKX2-5 transgenic mice. This proved rather difficult, as repeated attempts over several years yielded only one transgenic line expressing NKX2-5 (the TgNkx2-5). This is probably a reflection of the sensitivity of the heart to varying NKX2-5 levels (42) (43) (44) . It is likely that the moderate over-expression of NKX2-5 in the hearts of TgNkx2-5 mice (2-to 3-fold) enabled them to survive, albeit with a shortened lifespan (Fig. 4) . Importantly, for the purposes of this study, NKX2-5 was expressed in skeletal muscle. Although over-expression of NKX2-5 did not have any overt effects on the histology of the skeletal muscle, the deleterious effects were clearly evident in the molecular effects on Myog and miR-1 (Fig. 4) and in functional assays such as grip strength and treadmill running (Supplementary Material, Fig. S6 ). Furthermore, the beneficial and detrimental effects on these phenotypes of decreasing or increasing (respectively) the amount of NKX2-5 present in our 5 -313 mice (Fig. 5) demonstrate the functional relevance of NKX2-5 as a modifier of skeletal muscle phenotypes in RNA toxicity.
How does NKX2-5 do this? The consequences of modulating NKX2-5 levels in mice with RNA toxicity provided some clues. RNA toxicity in the 5 -313 mice led to a more severe DM1-like histopathology and a significant skew in fiber size towards small fibers (Supplementary Material, Fig. S9 and Fig. 5 ). Overexpression of NKX2-5 clearly worsened this while haploinsufficiency had noticeable benefits (Fig. 5) . This suggested that NKX2-5 somehow impaired the response to damage caused by the toxic RNA. The CTX experiments enabled us to study this in a more defined and well-characterized manner, revealing that TgNkx2-5 mice had a regeneration defect in response to muscle damage (Figs 6 and 7). Our results with CTX injection in the 5 -313 mice show that delayed muscle regeneration is an early effect of RNA toxicity, even before the onset of detectable muscle histopathology ( Fig. 6B and C) . Satellite cells are the key mediators of muscle regeneration. Our analyses of the TgNkx2-5 mice and the DM5-Dox+ve mice, showing the reduced number of PAX7+ve nuclei in response to induced damage, point to defects in satellite cell function and subsequent progression to committed myoblasts capable of regeneration (Fig. 7) . These potentially synergistic effects of RNA toxicity and NKX2-5 over-expression are consistent with the concept of defective regenerative capacity in DM1, where repeated cycles of damage are not met with an adequate or sufficient regenerative response, leading to progressively worsening muscle pathology.
Muscular dystrophy in DM1 is likely due to a complex set of changes in gene expression induced by the toxic RNA, including effects on RNA-binding proteins such as MBNL1-3 and CELF1, a plethora of splicing defects and other as yet defined alterations. Here, we clearly show that NKX2-5 acts as a modifier of skeletal muscle pathology induced by RNA toxicity using correlative studies in human tissues, as well as a variety of mechanistic studies using cell culture and mouse models. These results support the hypothesis that increased expression of NKX2-5 in skeletal muscle is deleterious to myogenesis and muscle regeneration and contributes to muscle wasting and weakness caused by RNA toxicity.
MATERIALS AND METHODS
Ethical statement
All studies on human subjects were done under the auspices of the University of Virginia Institutional Review Board. All studies utilizing mice were done under the auspices of the University of Virginia Animal Care and Use Committee.
Patient samples
Human tissue samples were obtained from the University of Miami Tissue Bank, Dr Charles A. Thornton (University of Rochester, USA) and Dr Laura P. Ranum (University of Minnesota, USA).
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All DM1 (n¼ 8) and DM2 (n ¼ 2) tissues were from patients with diagnoses confirmed by molecular analyses. Muscle samples from patients with other muscle disorders: DMD (n ¼ 3), X-linked myopathy (n ¼ 1) as well as four non-muscular dystrophy tissues were also studied. All studies were done under the auspices of the University of Virginia Institutional Review Board. Quantitative histopathological grading was done as outlined in the supplemental methods.
Transgenic mice
Characterization of transgenic mice are described elsewhere (13) . We used two different DMPK 3 ′ UTR mRNA transgenic lines (5 -313 and 5-336) (FVB strain). Chloride channel 1 (SWR/J-Clcn1 adr-mto /J), MDX (C57BL/10ScSn-Dmd mdx /J) and GFP (C57BL/6-Tg (tetO-CDK5R1/GFP) 337Lht/J) mice were obtained from The Jackson Laboratory (Bar Harbor, Maine). Tissues from HSA-LR mice (22) (29) were provided by Dr R.P. Harvey. The TgNkx2-5 line was generated using the 5 -313 cloning vector but replacing the GFP and DMPK 3 ′ UTR with the cDNA for mouse Nkx2-5. Unfortunately, the resultant mouse line was unresponsive to doxycycline but was constitutively active.
Histology
H&E staining was done using standard procedures. Fiber size was determined by measuring cross-sectional area of each muscle fiber in a ×200 image of H&E-stained skeletal muscle. Five mice per group were analyzed and for each mouse, at least three images were analyzed.
Cell culture and reagents C2C12 myoblasts were maintained at subconfluent densities in Dulbecco's modified eagle medium (DMEM) supplemented with 10% fetal bovine serum (growth media, GM). To induce myoblast differentiation, cells were grown to 90% confluence and then cultured in differentiation media containing DMEM supplemented with 2% horse serum (HyClone w ). Differentiation media was replaced every 24 h. Stable C2C12 clones expressing the GFP-DMPK 3 ′ UTR with either (CTG) 5 or (CTG) 200 were obtained by transfection using the Nucleofector TM kit from Amaxa TM and selection for 9 days with 800 mg ml 21 G418 (Gibco w ). Four independent clones for each construct were used for subsequent analyses. Stable C2C12 clones expressing NKX2-5 were obtained by transfection using a PCDNA3.1-HisC-Nkx2-5 (open reading frame), and control cell lines with PCDNA3.1 (Invitrogen, Inc.). Eight clones for each construct were used for subsequent analyses. Primer sequences and methods for generating shRNA constructs used in this study are detailed in Supplementary Material, Table S6 .
RNA analyses
Total RNA was extracted from tissues collected in isopentane and flash frozen in liquid nitrogen (10) . Total RNA (1 mg) was used for making cDNA using QuantiTect TM Reverse Transcription Kit (Qiagen w ) and then subjected to PCR using genespecific primers. qRT-PCR was done using the BioRad iCycler TM and BioRad's kits using manufacturer's protocols and detected with SYBRGreen TM dye. miR-1 was analyzed using Invitrogen's NCode miRNA First-Strand cDNA Synthesis and qRT-PCR kit form 1 mg total RNA. Primer sequences are given in Supplementary Material, Tables S4 and S5. All reactions were performed with technical duplicates except in the case of miR-1 in which technical triplicates were used. Biological replicates were always greater than three and indicated in the text and figure legends. Data normalization was accomplished using the endogenous control (Gapdh or U6), and the normalized values were subjected to a 2 2DDCt formula to calculate the fold change between the control and experimental groups. All splicing assays were done in at least three mice or more per group. mRNA splicing primers and conditions have been previously reported (15) .
CTX and regeneration
DM5-313
+/2 mice were either kept on normal water (uninduced) or given 0.2% doxycycline (induced) for 14 days. After 14 days, the gastrocnemius muscles in each mouse was injected with either 10 mM CTX or PBS. After another 14 days, tissues were harvested, sectioned and stained. The muscle fiber size was determined by measuring the cross-sectional area of each muscle fiber in a ×200 image of H&E-stained skeletal muscle. Five mice per group were analyzed and for each mouse, at least three images were analyzed using AxioVision V4.8.2.0 (Carl Zeiss MicroImaging). PAX7 immunofluorescence was done with tissues collected 5 days after CTX injection. Flash frozen 6 mm sections were fixed with 4% paraformaldehyde. Primary antibodies were anti-Pax7 (DSHB, Pax7-c; 1:50 dilution) and anti-laminin (Sigma, #L9393; 1:200 dilution). Secondary antibodies were from Molecular Probes TM (1:1000 dilutions).
Immunoblotting and immunofluorescence
Tissues were collected in isopentane and flash frozen in liquid nitrogen. Protein extracts were made in radioimmunoprecipitation assay buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% NP40, 0.5% Na-deoxycholate, 0.1% sodium dodecyl sulfate [SDS] ) and protease inhibitor (Roche). Protein extracts from cells were made in cell lysis buffer (50 mM HEPES, pH 7.6, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1.5 mM MgCl 2 , 0.1 mM EDTA and 0.5 mM DTT) with protease inhibitors. Extracts were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE) and assayed by western blotting. The following antibodies were used: NKX2-5 [Santa Cruz Biotechnology w (SCBT), 1:1000 for NKX2-5 in C2C12] followed by rabbit anti-goat (SCBT, 1:5000); MYOD1 (BD Pharmingen (SCBT, 1:250) followed by goat anti-rabbit (Pierce w , 1:20 000). Immunofluorescence for MHC and NKX2-5 were performed as previously described (6) . Microscopy was performed using an Olympus IX 50 inverted microscope with fluorescent attachments and images were captured with a CCD camera.
Statistical analyses
Standard statistical methods were employed using Minitab 16.1.0 (Minitab, Inc.). Data sets were analyzed for outliers using the Grubb's test, and once outliers were removed, the data were analyzed for normality. If normal, two-tailed student's t-tests were employed to assess significance, with attention paid to equal versus unequal variance and the appropriate adjustment made. Mann -Whitney assessment was used for non-normal data. Multiple comparisons were done using a one-Way ANOVA with Tukey's multiple comparisons. 
AUTHOR CONTRIBUTIONS
